30, the drugmaker had a remaining $8.2 billion in share repurchases authorized as part of the December 2018 program and a previous one. In December 2018, Merck's board authorized a $10 billion share repurchase program, of which it said it had spent $3.73 billion. RELATED: The top 10 pharma R&D budgets in 2018- Merck & Co. The year before, the equation was flipped, with Merck spending $7.59 billion on R&D and $7.06 billion on buybacks and dividends over the three-quarter period. The drugmaker shelled out an additional $4.29 billion in dividends in the first three quarters of 2019 compared with $3.9 billion the year before.īut in a rarity on our list, Merck's total shareholder payouts and R&D spending were almost level in 2019 at $8.02 billion and $7.32 billion, respectively. Merck dropped $3.73 billion in stock buybacks in the first nine months of 2019, about $570 million more than what it spent on repurchases over the same time period in 2018.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |